DOYLESTOWN, PA--(Marketwire - March 03, 2008) - QuantRx® Biomedical Corporation (OTCBB: QTXB), a broad-based diagnostics company focused on the development and commercialization of innovative diagnostic products based on its patented technology platforms for the worldwide healthcare industry, today announced that FluoroPharma, Inc., a company developing breakthrough cardiovascular molecular imaging agents for the PET market, presented positive Phase I safety results for CardioPET, its lead product. The trial was designed to evaluate safety, distribution and dosimetry of CardioPET as a PET tracer for myocardial imaging in healthy subjects and patients with Coronary Artery Disease (CAD). Dr. David Elmaleh, Chairman and scientific founder of FluoroPharma, presented findings from the Phase I trial at the "Clinical Trials Update" session at a Society of Nuclear Medicine conference in Denver, Colorado.
